Acquired hemophilia A · 5 regimens
Cost vs Efficacy · 1 point
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
Prednisone monotherapy Variant #11 Partial | — | R 39 | 7d | ~2.2 mo | ~14.1 mo | ~1 | ~R 39 PFS proxy · indirect | 8 |
Cyclophosphamide and Prednisone Variant #02 | — | R 17 | — | — | ~10.0 mo | ~1 | ~R 17 PFS proxy · indirect | 1 |
Cyclophosphamide and Prednisolone Variant #01 | — | R 13 | — | — | — | ~1 | ~R 13 indirect | — |
Prednisolone monotherapy Variant #03 | — | R 4 | 84d | — | — | ~1 | ~R 4 PFS proxy · indirect | 1 |
Rituximab monotherapy Variant #09 Partial | — | — | 28d | ~20.3 mo | — | ~1 | — | 20 |
5 of 5 regimens shown